PMID- 17298741
OWN - NLM
STAT- MEDLINE
DCOM- 20090924
LR  - 20150313
VI  - 26
IP  - 2
DP  - 2007 Feb
TI  - [Antitumor efficacy of fusion cells from esophageal carcinoma cells and dendritic 
      cells as a vaccine in vitro].
PG  - 137-41
AB  - BACKGROUND & OBJECTIVE: Dendritic cells (DCs) are antigen-presenting cells, and 
      DC-based fusion vaccine of DCs with tumor cells can induce specific immune 
      response against tumor cells effectively. This study was to investigate the 
      antitumor immunity efficacy of fusion vaccine of DCs with human esophageal 
      carcinoma EC109 cells in vitro. METHODS: Peripheral blood mononuclear cells 
      (PBMCs) from healthy volunteers were isolated, and cultured with recombinant 
      human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) and 
      interleukin-4 (IL-4) to generate DCs. Fusion cells of DCs with EC109 cells were 
      generated by polyethylene glycol (PEG) protocol. The T-cell proliferation 
      response stimulated by DC/EC109 cells was detected by MTT assay. The killing 
      efficacy of cytotoxic T lymphocytes (CTLs), activated by DC/EC109 cells, on EC109 
      cells was evaluated by LDH assay in vitro, and compared with the killing efficacy 
      on human gastric carcinoma SGC7901 cells and human breast cancer MCF7 cells. 
      RESULTS: The highest fusion efficiency of DCs with EC109 cells was 22.25%. The 
      stimulating efficacy of DC/EC109 cells on the proliferation of T cells was 
      significantly higher than those of DCs and EC109 cells (P<0.05). DC/EC109 cells 
      induced specific CTLs against EC109 cells, and the killing efficacy of the CTLs 
      was significantly higher for EC109 cells than for SGC7901 cells or MCF7 cells 
      (P<0.05). CONCLUSION: C/EC109 fusion vaccine can induce specific antitumor 
      response against EC109 cells effectively.
FAU - Deng, Yong-Jun
AU  - Deng YJ
AD  - State Key Laboratory of Oncology in South China, Guangzhou, Guangdong, PR China. 
      xiajc@hotmail.com
FAU - Xia, Jian-Chuan
AU  - Xia JC
FAU - Zhou, Jun
AU  - Zhou J
FAU - Wang, Qi-Jing
AU  - Wang QJ
FAU - Zhang, Peng-Yuan
AU  - Zhang PY
FAU - Zhang, Lan-Jun
AU  - Zhang LJ
FAU - Rong, Tie-Hua
AU  - Rong TH
LA  - chi
PT  - English Abstract
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - China
TA  - Ai Zheng
JT  - Ai zheng = Aizheng = Chinese journal of cancer
JID - 9424852
RN  - 0 (Cancer Vaccines)
RN  - 0 (MUC1 protein, human)
RN  - 0 (Mucin-1)
SB  - IM
MH  - Cancer Vaccines/*immunology
MH  - Cell Fusion
MH  - Cell Line, Tumor
MH  - Cell Proliferation
MH  - Cytotoxicity, Immunologic/*immunology
MH  - Dendritic Cells/cytology/*immunology
MH  - Esophageal Neoplasms/*immunology/metabolism/pathology
MH  - Humans
MH  - Hybrid Cells/cytology/*immunology
MH  - Mucin-1/metabolism
MH  - T-Lymphocytes, Cytotoxic/immunology
EDAT- 2007/02/15 09:00
MHDA- 2009/09/25 06:00
CRDT- 2007/02/15 09:00
PHST- 2007/02/15 09:00 [pubmed]
PHST- 2009/09/25 06:00 [medline]
PHST- 2007/02/15 09:00 [entrez]
AID - 1000-467X200702137 [pii]
PST - ppublish
SO  - Ai Zheng. 2007 Feb;26(2):137-41.